Aberrant activity of ADAM proteases has long been implicated in tumorigenesis and cancer progression [89,90], and more recently, elevated ADAM10 expression has been associated with poor clinical response to trastuzumab in HER2-positive breast cancers [91,92]. This evidence concerns the gene ERBB2 and breast carcinoma.